← Back to Clinical Trials
Recruiting NCT06737289

NCT06737289 SURGICAL GUIDES EFFECTIVENESS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06737289
Status Recruiting
Phase
Sponsor Universidad Complutense de Madrid
Condition Atrophic Maxilla
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-12-11
Primary Completion 2025-06-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Surgical Guide

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-12-11 with a primary completion date of 2025-06-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The use of zygomatic implants is a technique that is becoming more and more widespread in daily clinical practice, however, few professionals feel safe and confident in performing this type of procedure. We therefore believe that a line of research focused on simplifying this technique will have an extraordinary impact on the safety of both patients and surgeons. Currently, new surgical guides have emerged that guarantee greater precision in the placement of zygomatic implants. However, no comparative clinical studies have yet been performed to evaluate the degree of accuracy of guided implant placement compared to the conventional freehand technique.

Eligibility Criteria

Inclusion Criteria: • Age between 18-80 years of age, patients who sign the informed consent form and patients who consent to undergo preoperative and postoperative orthopantomography and CT scans. Exclusion Criteria: * Smoking (more than 10 cigarettes per day). * Alcoholism (more than 25g/day in women and more than 40g/day in men according to WHO criteria), * Oncological treatment (history of treatment in the last 6 months or current treatment with chemotherapy or radiotherapy). * History of head and neck radiotherapy. * Allergic to anesthetics or antibiotics.

Contact & Investigator

Central Contact

Jesus Torres, PhD

✉ jesus.torres@ucm.es

📞 653050071

Principal Investigator

JEsus Torres, PhD

PRINCIPAL INVESTIGATOR

UCM

Frequently Asked Questions

Who can join the NCT06737289 clinical trial?

This trial is open to participants of all sexes, studying Atrophic Maxilla. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06737289 currently recruiting?

Yes, NCT06737289 is actively recruiting participants. Contact the research team at jesus.torres@ucm.es for enrollment information.

Where is the NCT06737289 trial being conducted?

This trial is being conducted at Madrid, Spain, Madrid, Spain.

Who is sponsoring the NCT06737289 clinical trial?

NCT06737289 is sponsored by Universidad Complutense de Madrid. The principal investigator is JEsus Torres, PhD at UCM. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology